Piper Jaffray Cos. restated their neutral rating on shares of Clovis Oncology Inc. (NASDAQ:CLVS) in a research report sent to investors on Wednesday. Piper Jaffray Cos. currently has a $42.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on the company. Credit Suisse Group AG reaffirmed an outperform rating and set a $41.00 price target on shares of Clovis Oncology in a report on Monday. Stifel Nicolaus set a $45.00 price target on Clovis Oncology and gave the company a buy rating in a report on Wednesday, October 5th. Zacks Investment Research downgraded Clovis Oncology from a buy rating to a hold rating in a report on Tuesday, October 4th. SunTrust Banks Inc. upped their price target on Clovis Oncology from $38.00 to $50.00 and gave the company a buy rating in a report on Friday, September 23rd. Finally, Janney Montgomery Scott downgraded Clovis Oncology from a buy rating to a neutral rating and upped their price target for the company from $35.00 to $36.00 in a report on Wednesday, September 21st. Seven equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Clovis Oncology currently has an average rating of Buy and a consensus target price of $36.39.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Shares of Clovis Oncology (NASDAQ:CLVS) traded down 0.15% on Wednesday, reaching $32.63. The company’s stock had a trading volume of 656,569 shares. The company’s market capitalization is $1.26 billion. The company’s 50-day moving average is $30.54 and its 200 day moving average is $18.97. Clovis Oncology has a 12-month low of $11.57 and a 12-month high of $109.18.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.13) by $0.06. During the same period in the prior year, the company earned ($2.10) EPS. Equities analysts anticipate that Clovis Oncology will post ($9.25) earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the stock. Alps Advisors Inc. raised its stake in Clovis Oncology by 25.1% in the second quarter. Alps Advisors Inc. now owns 53,924 shares of the biopharmaceutical company’s stock valued at $740,000 after buying an additional 10,828 shares during the last quarter. Candriam Luxembourg S.C.A. raised its stake in Clovis Oncology by 46.9% in the second quarter. Candriam Luxembourg S.C.A. now owns 47,000 shares of the biopharmaceutical company’s stock valued at $645,000 after buying an additional 15,000 shares during the last quarter. Old Mutual Global Investors UK Ltd. bought a new stake in Clovis Oncology during the second quarter valued at about $1,234,000. Fox Run Management L.L.C. bought a new stake in Clovis Oncology during the second quarter valued at about $154,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Clovis Oncology during the first quarter valued at about $233,000. 98.46% of the stock is owned by institutional investors and hedge funds.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

5 Day Chart for NASDAQ:CLVS

Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.